Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
The American Journal of Clinical Nutrition
|
January 24, 2003
Calcium intake and adiposity
Shamik J Parikh, Jack A Yanovski
JAMA Surgery
|
August 21, 2025
Corrections and Clarifications to Address Concerns About Reporting of Studies of Bioengineered Arteries for Repair of Extremity Vascular Injuries
Shamik J Parikh, Laura E Niklason
Postgraduate Medicine
|
February 16, 2016
Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials
Kristina Johnsson, Eva Johnsson, Traci A Mansfield, et al.
Journal of Diabetes and Its Complications
|
July 16, 2013
Urinary tract infections in patients with diabetes treated with dapagliflozin
Kristina M Johnsson, Agata Ptaszynska, Bridget Schmitz, et al.
Journal of Diabetes and Its Complications
|
June 29, 2013
Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin
Kristina M Johnsson, Agata Ptaszynska, Bridget Schmitz, et al.
Diabetes Care
|
October 29, 2002
Indices of insulin action, disposal, and secretion derived from fasting samples and clamps in normal glucose-tolerant black and white children
Gabriel I Uwaifo, Erica M Fallon, Jeff Chin, et al.
Diabetes & Vascular Disease Research
|
December 13, 2006
Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy
Dahong Yu, Susan J Murdoch, Shamik J Parikh, et al.
Journal of the American Dietetic Association
|
May 1, 2007
Validation of three food frequency questionnaires to assess dietary calcium intake in adults
Nancy G Sebring, Blakeley I Denkinger, Carolyn M Menzie, et al.
Drug Safety
|
August 7, 2014
Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events
Agata Ptaszynska, Kristina M Johnsson, Shamik J Parikh, et al.
Journal of the American Geriatrics Society
|
June 4, 2014
Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension
Lawrence A Leiter, William T Cefalu, Tjerk W A de Bruin, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
The American Journal of Clinical Nutrition
|
January 24, 2003
Calcium intake and adiposity
Shamik J Parikh, Jack A Yanovski
JAMA Surgery
|
August 21, 2025
Corrections and Clarifications to Address Concerns About Reporting of Studies of Bioengineered Arteries for Repair of Extremity Vascular Injuries
Shamik J Parikh, Laura E Niklason
Postgraduate Medicine
|
February 16, 2016
Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials
Kristina Johnsson, Eva Johnsson, Traci A Mansfield, et al.
Journal of Diabetes and Its Complications
|
July 16, 2013
Urinary tract infections in patients with diabetes treated with dapagliflozin
Kristina M Johnsson, Agata Ptaszynska, Bridget Schmitz, et al.
Journal of Diabetes and Its Complications
|
June 29, 2013
Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin
Kristina M Johnsson, Agata Ptaszynska, Bridget Schmitz, et al.
Diabetes Care
|
October 29, 2002
Indices of insulin action, disposal, and secretion derived from fasting samples and clamps in normal glucose-tolerant black and white children
Gabriel I Uwaifo, Erica M Fallon, Jeff Chin, et al.
Diabetes & Vascular Disease Research
|
December 13, 2006
Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy
Dahong Yu, Susan J Murdoch, Shamik J Parikh, et al.
Journal of the American Dietetic Association
|
May 1, 2007
Validation of three food frequency questionnaires to assess dietary calcium intake in adults
Nancy G Sebring, Blakeley I Denkinger, Carolyn M Menzie, et al.
Drug Safety
|
August 7, 2014
Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events
Agata Ptaszynska, Kristina M Johnsson, Shamik J Parikh, et al.
Journal of the American Geriatrics Society
|
June 4, 2014
Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension
Lawrence A Leiter, William T Cefalu, Tjerk W A de Bruin, et al.
Page
of 2